<DOC>
	<DOC>NCT01757483</DOC>
	<brief_summary>This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.</brief_summary>
	<brief_title>Canadian Ticagrelor Survey</brief_title>
	<detailed_description>Effectiveness of risk minimisation interventions for ticagrelor in Canada</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>N/A (All prescribers will be contacted for participation) Participation in a previous wave of the survey.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>